The Q&A session at the 2025 NSF Pharma Biotech Conference explored how pharmaceutical and biotechnology manufacturers can strengthen contamination control strategies (CCS), embed a sustainable quality culture, and develop the workforce capabilities needed to meet evolving regulatory expectations.
The discussion underscored the growing importance of aligning employee behaviours with compliance objectives, while also addressing the industry’s ongoing challenges around regulatory benchmarking and operational consistency.
Key themes from the panel discussion included:
Quality culture as a core compliance driver
Panelists noted that regulators increasingly view quality culture as a critical factor influencing inspection outcomes. Rather than being treated as a procedural requirement, quality culture must be continuously assessed, reinforced and embedded across all levels of an organisation.
Building effective contamination control strategies
With EU GMP Annex 1 now firmly established, manufacturers continue to face challenges in developing comprehensive CCS frameworks. The session highlighted the role of advanced technologies, risk-based approaches and robust operator training in reducing contamination risks and minimising human error in cleanroom environments.
Strengthening workforce capability
The panel also addressed the ongoing difficulty of recruiting and retaining experienced quality professionals. Speakers emphasised the value of continuous coaching, simplifying standard operating procedures (SOPs), and creating a culture in which employees feel confident to report deviations and concerns at an early stage. These measures were linked directly to reducing the “Cost of Poor Quality” and improving overall operational resilience.
